Phase II study of Carboplatin plus nab-Paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2014 Status changed from not yet recruiting to recruiting as reported by UMIN record.
- 27 Feb 2014 New trial record